Your browser doesn't support javascript.
loading
Effects of R&D Expenses Additional Deduction Policy on R&D Investment and Profitability of Pharmaceutical Manufacturing Industry / 中国药房
China Pharmacy ; (12): 1286-1293, 2021.
Article in Chinese | WPRIM | ID: wpr-877248
ABSTRACT
OBJECTIVE:To stu dy the effects of R&D expense additional deduction policy on R&D investment and profitability of pharmaceutical manufacturing industry , and to provide reference for improving R&D investment and profitability of pharmaceutical manufacturing industry. METHODS :Based on the data of Chinese pharmaceutical listed enterprises during 2012-2019,regression discontinuity design and descriptive method were adopted to analyze the effect of R&D expenses additional deduction policy on R&D investment and profitability of pharmaceutical manufacturing industry. RESULTS :Both R&D investment and the main business profit margin had significant “jump”at the policy cutoff point ,and the policy effect coefficient of the R&D expenses additional deduction policy on R&D investment and profitability of the pharmaceutical manufacturing industry were 0.310 and -1.197 respectively(P<0.001). The policy effect coefficient of the policy on R&D investment in the eastern region was 0.413(P<0.001),while the effect on central and western regions were not significant ;the policy effect coefficient of the policy on R&D investment of large-scale and small- and medium-scale pharmaceutical manufacturing industry were 0.502 and 0.264 respectively(P<0.001). CONCLUSIONS :On the whole ,R&D expenses additional deduction policy has a positive incentive impact on R&D investment of pharmaceutical manufacturing industry ,but does not have a positive incentive impact on the profitability which is greatly affected by other factors. The policy has regional differences in the incentive impact on R&D investment of pharmaceutical manufacturing industry ;the incentive impact of the policy on the R&D investment of large-scale pharmaceutical manufacturing industry is better than that of small-and medium-scale one. It is recommended to improve the R&D expenses additional deduction policy ,reasonably increase the profit margin of the pharmaceutical manufacturing industry ,adjust the policy for different regions and focus on guiding policies to favor small- and medium-scale pharmaceutical manufacturing industry,so as to improve the R&D investment and profitability of pharmaceutical manufacturing industry.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Health economic evaluation Language: Chinese Journal: China Pharmacy Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Health economic evaluation Language: Chinese Journal: China Pharmacy Year: 2021 Type: Article